11
Views
3
CrossRef citations to date
0
Altmetric
CASE REPORT

A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis

&
Pages 634-638 | Received 13 Apr 2008, Accepted 24 Jun 2008, Published online: 02 Jan 2014

References

  • Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002;44:196�8.
  • Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T-cell activation. mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest. 1991;87:940�8.
  • Kamada H, Itoh H, Shibata H, Koshio T, Hayashi A, Nakagami K. Inhibitory mechanism of mizoribine on the antibody production of mouse B-cells stimulated with lipopolysaccharide. Jpn J Pharmacol. 1997;74:323�30.
  • Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206�12.
  • Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int.. 2000;58:317�24.
  • Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, et al. Efficacy and safety of mizoribine for the treatment of Sjogren�s syndrome: a multicenter open-label clinical trial. Mod Rheumatol. 2007;17:464�9.
  • Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int. 2002;44:205�9.
  • Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34�45.
  • Saida K, Zhigang Z, Ozawa K, Konishi T, Saida T. Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome. Intern Med. 1999;38: 636�42.
  • Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005;64:28�34.
  • Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006; 16:214�9.
  • Fernandez LA, Lehmann R, Luzi L, Battezzati A, Angelico MC, Ricordi C, et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation. 1999;68:1532� 41.
  • Yoshida EM, Buczkowski AK, Sirrs SM, Elliott TG, Scudamore CH, Levin A, et al. Post-transplant diabetic ketoacidosis�a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series. Transpl Int. 2000;13:69�72.
  • Okubo S, Nakatani K. Two cases of rheumatoid arthritis complicated with saccharometabolic abnormality caused by mizoribine (in Japanese). Clinical Rheumatol Related Res. 2000;12:40�4.
  • Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342:301–7.
  • Metz SA, Rabaglia ME, Pintar TJ. Selective inhibitors of GTP synthesis impede exocytotic insulin release from intact rat islets. J Biol Chem. 1992;267:12517–27.
  • Li G, Segu VB, Rabaglia ME, Luo RH, Kowluru A, Metz SA. Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology. 1998;139: 3752–62.
  • Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274: 87–92.
  • Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39:709–16.
  • Yutsudo Y, Hasegawa Y, Takada T, Yamada H, Aoyama N, Morita S, et al. A case of rheumatoid arthritis (RA) with drug-induced acute pancreatitis due to mizoribine (in Japanese). Ryumachi. 1997;37:564–7.
  • Felig DM, Topazian M. Corticosteroid-induced pancreatitis. Ann Intern Med. 1996;124:1016–3.
  • Dhir R, Brown DK, Olden KW. Drug-induced pancreatitis: a practical review. Drugs Today (Bart). 2007;43:499–507.
  • Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol.. 2007;5:648-61. quiz 4.
  • Yamamoto M, Takahashi H, Naishiro Y, Isshiki H, Ohara M, Suzuki C, et al. Mikulicz's disease and systemic IgG4-related plasmacytic syndrome (SIPS) (in Japanese). Nihon Rinsho Meneki Gakkai Kaishi. 2008;31:1–8.
  • Hayakawa T, Naruse S, Kitagawa M, Kondo T. Clinical aspects of autoimmune pancreatitis in Sjogren's syndrome. Jop. 2001; 2:88–92.
  • Nair S, Yadav D, Pitchumoni CS. Association of diabetic ke-toacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000;95: 2795–800.
  • Pitchumoni CS, Agarwal N, Jain NK. Systemic complications of acute pancreatitis. Am J Gastroenterol. 1988;83:597–606.
  • Kahn D, Bourgeois JA. Acute pancreatitis and diabetic ketoaci-dosis in a schizophrenic patient taking olanzapine. J Clin Psychopharmacol. 2007;27:397–400.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.